Cargando…
Allele-specific silencing of the gain-of-function mutation in Huntington’s disease using CRISPR/Cas9
Dominant gain-of-function mechanisms in Huntington’s disease (HD) suggest that selective silencing of mutant HTT produces robust therapeutic benefits. Here, capitalizing on exonic protospacer adjacent motif–altering (PAM-altering) SNP (PAS), we developed an allele-specific CRISPR/Cas9 strategy to pe...
Autores principales: | Shin, Jun Wan, Hong, Eun Pyo, Park, Seri S., Choi, Doo Eun, Seong, Ihn Sik, Whittaker, Madelynn N., Kleinstiver, Benjamin P., Chen, Richard Z., Lee, Jong-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675467/ https://www.ncbi.nlm.nih.gov/pubmed/36040815 http://dx.doi.org/10.1172/jci.insight.141042 |
Ejemplares similares
-
PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington’s disease
por: Shin, Jun Wan, et al.
Publicado: (2022) -
CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington’s Disease
por: Kolli, Nivya, et al.
Publicado: (2017) -
CRISPR/Cas9 Mediated Therapeutic Approach in Huntington’s Disease
por: Alkanli, Suleyman Serdar, et al.
Publicado: (2022) -
Silencing of the Mutant Huntingtin Gene through CRISPR-Cas9 Improves the
Mitochondrial Biomarkers in an In Vitro Model of Huntington’s Disease
por: Dunbar, Gary L., et al.
Publicado: (2019) -
Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo
por: Tao, Yong, et al.
Publicado: (2023)